Dermatology is often dismissed as a cosmetic category, but medical dermatology, meaning psoriasis, atopic dermatitis, chronic non-healing wounds, and skin cancer, represents a large, visible, quality-of-life-driven disease burden with a well-worn regulatory and commercial path. Skin disease has also repeatedly served as an early clinical proving ground for immune mechanisms, including IL-17, IL-23, IL-4/IL-13, and JAK inhibition, some of which were later extended into asthma, inflammatory bowel disease, psoriatic arthritis, and other immune-mediated conditions, because skin is accessible, biopsiable, and visually measurable in a way few other organs are. That extension is not automatic: IL-23-selective blockade succeeded in inflammatory bowel disease, while IL-17 blockade did not and in some patients worsened Crohn’s disease, which is a useful reminder that skin validation does not guarantee identical behavior in every tissue. The diagnostic and device side, AI-assisted imaging for skin cancer triage and next-generation wound-care technology, adds a second, often underappreciated, investable layer, with FDA having authorized AI-based skin-lesion triage devices as clinician decision-support tools rather than autonomous diagnostics. For Sonnerie, a fundable pre-seed dermatology spinout usually pairs a university-originated mechanistic or imaging insight with an operator who has lived through a prior FDA or reimbursement cycle, and a plan to generate one discrete, de-risking human data point before a seed round.
What counts as medical dermatology, and why the distinction matters to investors
When Sonnerie evaluates dermatology, the category does not include cosmetic dermatology, injectables, laser aesthetics, or beauty devices. It means medical, non-cosmetic skin disease: chronic inflammatory conditions such as psoriasis and atopic dermatitis (eczema), wound care in diabetic and vascular populations, and skin cancer, from melanoma to the far more common basal and squamous cell carcinomas.
This distinction matters commercially and scientifically. Cosmetic dermatology is discretionary spend, sensitive to consumer confidence and largely uninsured. Medical dermatology, by contrast, sits inside the reimbursed pharmaceutical and device system, subject to the same FDA pathways, payer coverage dynamics, and standard-of-care displacement logic as any other chronic disease category. That means a dermatology therapeutic can be underwritten the way an investor underwrites any specialty-pharmacy or physician-administered drug: prevalence, current standard of care, unmet need at a defined line of therapy, and a plausible path to a differentiated label.
It also matters because skin disease is chronically undertreated relative to its burden. Public-health surveys have long shown that inflammatory skin conditions rank among the more common reasons for outpatient physician visits, and patient-reported quality-of-life burden in moderate-to-severe psoriasis and atopic dermatitis is comparable to that reported in other major chronic diseases, including sleep disruption, depression and anxiety, and impact on work productivity and relationships. That burden is visible, literally, which has made skin disease unusually well suited to patient advocacy, clinical trial recruitment, and endpoint measurement, all of which lower execution risk for a young company.
How large is the disease burden in psoriasis, atopic dermatitis, chronic wounds, and skin cancer
Psoriasis is a chronic, immune-mediated, relapsing skin disease that, by most public-health estimates, affects a meaningful single-digit percentage of adults in Western populations, with a smaller subset classified as moderate-to-severe and eligible for systemic or biologic therapy. It is also systemic in a way many people underestimate: a substantial share of psoriasis patients go on to develop psoriatic arthritis, and epidemiologic data has long associated psoriasis with elevated cardiovascular risk, making it a useful anchor disease for immunology platforms that aim to address inflammation beyond the skin.
Atopic dermatitis is, by most public-health accounts, the most common chronic inflammatory skin disease in children, and it also persists into or arises in adulthood for a significant population. Its hallmark, intractable itch and sleep disruption, makes it one of the clearer examples in medicine where a patient-reported symptom, pruritus, is both the chief complaint and a validated regulatory endpoint, which has simplified trial design for sponsors entering the space.
Chronic, non-healing wounds, diabetic foot ulcers, venous leg ulcers, and pressure injuries, represent a different kind of burden: high cost of care, high recurrence, amputation risk, and a population that skews toward older adults with diabetes and vascular disease, a population that is itself growing. Wound care sits at the intersection of dermatology, vascular surgery, endocrinology, and wound-specific reimbursement codes, and it remains one of the more underinvested corners of the category relative to its cost to health systems.
Public-health data has long shown skin cancer to be among the most commonly diagnosed cancer categories in fair-skinned populations worldwide. Basal cell and squamous cell carcinomas are rarely fatal but are extremely high in incidence and drive enormous cumulative procedural volume, biopsy, Mohs surgery, and excision, while melanoma, though far less common, accounts for the large majority of skin-cancer deaths, is highly curable when caught early, and is far harder to treat once metastatic. That asymmetry between incidence and mortality is precisely why early detection technology is such a natural investment thesis in this disease.
Why has dermatology repeatedly been a proving ground for new immune mechanisms, and where does that pattern break down
One of the more consistent patterns in immunology drug development is that a new mechanism is often de-risked in skin before it is trusted in other organs, though the pattern does not always transfer cleanly. IL-17 and IL-23 pathway biology was clinically validated in psoriasis before being carried into psoriatic arthritis and ankylosing spondylitis, where IL-17 blockade also proved effective. IL-23-selective blockade went on to succeed in inflammatory bowel disease as well, but IL-17 blockade did not: clinical trials found it ineffective in Crohn’s disease and, in some patients, associated with worsening of the condition, a result that has shaped how sponsors think about which cytokine target to advance into which tissue. IL-4 and IL-13 blockade was established in atopic dermatitis and asthma in close succession, reflecting a shared type 2 inflammatory circuit. JAK inhibition moved from rheumatoid arthritis into atopic dermatitis and alopecia areata as the safety and efficacy profile built in a visible, biopsiable tissue helped build physician and regulator confidence.
There are structural reasons skin plays this role. The organ is directly visible and photographable, which supports objective, reproducible severity scoring in a way that is harder to achieve for, say, joint pain or bowel inflammation. Skin is also easily and repeatedly biopsied with minimal risk, which gives translational teams direct access to tissue-level pharmacodynamic and mechanistic readouts, cytokine expression, immune cell infiltration, barrier gene expression, early in a program, often before a large efficacy trial is even funded. And because skin disease severity can be tracked with validated, non-invasive composite scores, sponsors can run smaller, faster proof-of-concept studies than are typically possible in an internal organ, generating an earlier and cheaper human data point.
For a pre-seed investor, this pattern is strategically useful in two directions, provided the second direction is treated with real scrutiny rather than assumed. First, it means a dermatology-first program can be a capital-efficient way to validate a new mechanism generally, a company may go on to propose expanding a validated mechanism into a systemic immune-mediated disease with a much larger addressable population, using the dermatology dataset as an anchor proof-of-mechanism. Second, and just as important, diligence on a new dermatology asset should always ask the mirror question: does the biology of this specific tissue, cytokine network, and disease process actually generalize to the second indication being pitched, or does it only sound like it should, since the IL-17-in-IBD experience is a concrete example of a mechanism that read as promising in skin and did not carry over.
Where do imaging, diagnostics, and wound-care devices fit into the dermatology thesis
Dermatology’s device and diagnostic layer is often underweighted relative to the therapeutics side, but it addresses a distinct and arguably more solvable problem: triage. The core clinical bottleneck in skin cancer is not a lack of effective treatment for early lesions, it is the shortage of dermatologist visit capacity and the resulting delay between a suspicious lesion appearing and a biopsy being read. Imaging-based triage tools, dermoscopy-linked software, whole-body photography with lesion tracking, and machine-learning classifiers trained to flag probable malignancy, are aimed squarely at compressing that delay and at directing scarce biopsy and specialist capacity toward the lesions most likely to matter, particularly melanoma, where early detection changes outcomes substantially.
The regulatory bar for this category has become clearer in recent years. FDA has authorized AI-enabled dermatologic imaging devices, including at least one intended for use by non-dermatologist physicians in primary care to evaluate suspicious lesions, generally positioned as adjunctive decision-support tools that produce a risk score or classification to guide a clinician’s referral or biopsy decision, rather than to autonomously diagnose. That precedent matters for a spinout: it establishes a realistic device classification, historically via a De Novo pathway for a first-of-kind device and a 510(k)-style pathway for later entrants once a predicate exists, and it clarifies that the commercially durable claim is usually sensitivity-preserving triage, not replacement of the biopsy. It is also worth noting that early pivotal data for this category has drawn regulatory attention to performance across skin tones, since training and validation cohorts have sometimes underrepresented darker skin, which is now an explicit post-market and diligence consideration.
Wound care technology is a second, distinct device thesis: advanced dressings, bioengineered skin substitutes, negative-pressure and oxygen-based therapies, and increasingly sensor-embedded dressings that track wound-bed biomarkers such as pH, moisture, or bioburden to flag infection or non-healing trajectory before it becomes clinically obvious. Because chronic wounds are reimbursed through a mix of Medicare wound-care codes and hospital cost-avoidance budgets, the commercial pathway looks different from a typical drug launch, adoption often depends as much on health-system economics and nursing workflow as on a randomized trial, which is a distinct diligence skill Sonnerie weighs heavily for device-oriented spinouts in this space.
What are the regulatory and commercial dynamics unique to dermatology
Dermatology drug development benefits from decades of regulatory precedent. Composite severity indices for psoriasis and atopic dermatitis are well established with regulators, itch and quality-of-life instruments are accepted patient-reported endpoints, and FDA has cleared a now-familiar succession of biologics and small molecules through this pathway, which lowers approval-path uncertainty relative to therapeutic areas with less standardized endpoints. That said, the category is also crowded at the more advanced, systemic end, moderate-to-severe psoriasis and atopic dermatitis both have multiple approved biologics and oral therapies, so a new asset generally needs a clear differentiation thesis: a meaningfully better efficacy or speed-of-onset profile, an oral alternative to an injectable, a safety advantage, or a defined position in patients who fail existing biologics.
Because dermatologic disease is so visible, it is also unusually well suited to patient-reported outcome capture, photographic real-world evidence, and payer negotiations grounded in quality-of-life data, which can support pricing and access arguments beyond a pure efficacy claim. At the same time, visibility cuts both ways: cosmetic outcome and tolerability, itch, burning, application-site reaction, matter more to real-world adherence in dermatology than in many internal-organ diseases, because patients see and feel the treated area daily, and a topical or biologic program that ignores this dimension in its target product profile tends to underperform commercially even when pivotal-trial efficacy looks strong.
On the device and diagnostic side, reimbursement is often the more common gating factor than regulatory clearance itself: a cleared AI-triage tool or advanced wound dressing still needs a durable coding or bundled-payment pathway, and health systems adopt slowly unless the economic case, reduced biopsy volume, reduced amputation rate, shorter time-to-heal, is unambiguous and easy for a hospital value-analysis committee to model.
What does a fundable pre-seed dermatology spinout look like to Sonnerie
Sonnerie is a pre-seed and seed investor in healthcare and life sciences, focused on university spinouts and operator-led teams, and dermatology is evaluated with the same first-institutional-check discipline applied across the portfolio. A dermatology company earns diligence attention when it starts from a genuine mechanistic, imaging, or materials insight originating in an academic lab, rather than a reformulation or me-too positioning play, and when the founding or operating team includes someone who has actually lived through a prior FDA submission, biologics launch, or reimbursement negotiation in immunology, oncology, or wound care.
For a therapeutic asset, we look for a defined patient segment where the company can generate one discrete, interpretable human or ex vivo human-tissue data point before a seed round, a small biopsy-based pharmacodynamic study, a proof-of-mechanism readout in skin-derived organoid or explant models, or an early biomarker signal, rather than requiring a full Phase 2 to know whether the biology is real. Because skin is biopsiable and disease severity is visually and instrumentally measurable, dermatology is one of the more capital-efficient places in immunology to generate that early truth-revealing data point relative to systemic disease areas, though as the IL-17-in-IBD experience shows, that data point still needs to be interpreted with tissue-specific caution when a company argues for expansion beyond skin.
For a diagnostic or device asset, we look for a clearly defined clinical bottleneck, biopsy triage capacity, time-to-detection in melanoma, non-healing wound identification, an achievable regulatory classification informed by existing FDA precedent in the category, and early clinical or retrospective imaging data that speaks to sensitivity in the population that matters most, not aggregate accuracy across easy cases. In both cases, we discount teams that lead with a large addressable market slide and cannot yet answer, in plain language, what specific experiment or dataset would change our mind about the mechanism or algorithm.
Frequently asked diligence questions we ask ourselves before writing a check
Is the disease population and line of therapy specific enough to size realistically, or is the pitch anchored to the entire psoriasis or atopic dermatitis prevalence rather than the addressable moderate-to-severe, biologic-eligible, or treatment-refractory subset that the asset would actually serve. Does the mechanism have a plausible, biologically specific expansion pathway beyond skin, and if so, has the team thought through why this cytokine or pathway should behave the same way in a second tissue, or is dermatology being treated as a dead-end indication rather than a proving ground. For device and imaging assets, does the sensitivity data hold up in the hardest subgroup, darker skin tones, atypical or early lesions, rather than only in a curated benchmark dataset, since skin cancer imaging tools have a documented history of underperforming on underrepresented skin types when training and validation data are not deliberately diversified.
We also ask whether the founding team has a realistic view of how crowded the advanced end of the market already is. Multiple approved biologics and JAK inhibitors already compete for moderate-to-severe psoriasis and atopic dermatitis patients, so a new therapeutic candidate needs a specific, defensible reason a physician or payer would switch, not just non-inferiority. Finally, we ask what the operator on the team has actually done before, because dermatology’s regulatory and commercial path is well trodden but not simple, and pre-seed execution risk is disproportionately a team-execution question rather than a science question once the underlying mechanism or imaging signal is credible.
Frequently asked questions
Is dermatology investing the same as investing in cosmetic or aesthetic skincare companies?
No. Sonnerie’s dermatology thesis is limited to medical, non-cosmetic skin disease, psoriasis, atopic dermatitis, chronic wounds, and skin cancer, which sit inside the reimbursed pharmaceutical, device, and diagnostic system and are underwritten like any other chronic disease category. Cosmetic dermatology, injectables, lasers, and aesthetic devices are a different, largely discretionary-spend category that Sonnerie does not focus on.
Why has dermatology so often been an early disease where a new immune-targeting drug mechanism is tested?
Skin is directly visible, easily and repeatedly biopsied with minimal risk, and its disease severity can be tracked with validated, non-invasive composite scores. That combination lets sponsors generate an interpretable human efficacy and tissue-level mechanistic readout faster and more cheaply than is typically possible in an internal organ, which is why mechanisms such as IL-17 and IL-23 blockade, IL-4/IL-13 blockade, and JAK inhibition were clinically validated in skin disease before being carried into psoriatic arthritis, ankylosing spondylitis, asthma, and alopecia areata. The pattern is not universal: IL-23-selective blockade went on to succeed in inflammatory bowel disease, while IL-17 blockade did not and in some patients worsened Crohn’s disease, a reminder that skin validation does not guarantee the same mechanism will behave identically in every tissue.
What is the difference between how skin cancer incidence and skin cancer mortality should shape an investment thesis?
Basal and squamous cell carcinomas are extremely common but rarely fatal, while melanoma is far less common but accounts for the large majority of skin-cancer deaths, and its prognosis depends heavily on how early it is detected. That asymmetry is why early-detection imaging and triage technology, aimed at directing scarce dermatologist and biopsy capacity toward the lesions most likely to be dangerous, is a distinct and compelling investment thesis from therapeutics aimed at treating already-diagnosed disease.
What regulatory pathway do AI-based skin imaging or lesion-triage tools typically follow?
FDA has authorized AI-enabled dermatologic imaging devices, including tools intended to help non-dermatologist physicians evaluate suspicious skin lesions, as adjunctive decision-support devices that produce a risk score or classification to guide a clinician’s referral or biopsy decision rather than to autonomously diagnose. The first device of a given kind has typically gone through a De Novo pathway, which then creates a classification that later, similar devices can use to pursue a 510(k) pathway. That precedent shapes the realistic regulatory strategy for a new imaging spinout and clarifies that the durable commercial claim is usually sensitivity-preserving triage rather than replacement of biopsy.
What makes a pre-seed dermatology spinout fundable in Sonnerie’s view?
A credible academic origin for the mechanistic, imaging, or materials insight, an operator on the team who has lived through a prior FDA submission or reimbursement cycle, and a concrete, near-term plan to generate one discrete, interpretable human or human-tissue data point, a biopsy-based pharmacodynamic study, an early biomarker signal, or real-world sensitivity data in a hard subgroup, that would meaningfully change an investor’s confidence in the underlying science before a seed round.
Is chronic wound care considered part of the dermatology investment category?
Yes, in Sonnerie’s framing chronic, non-healing wounds, diabetic foot ulcers, venous leg ulcers, and pressure injuries, are treated as part of medical dermatology because they sit at the intersection of skin biology, vascular and metabolic disease, and dedicated wound-care reimbursement pathways. Wound-care technology, advanced dressings, bioengineered skin substitutes, and sensor-embedded dressings, remains one of the more underinvested corners of the category relative to its cost burden on health systems.